Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONKEMI: Nasal Ketamine vs Oral Morphine for Breakthrough Cancer Pain
NCT02591017Phase 3Terminated
- Sponsor
- University Hospital Basel
- Start
- Feb 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in breakthrough cancer pain (BTcP), sponsored by University Hospital Basel. Started Feb 2015; status: terminated.
02
Drugs
ketamine
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT02591017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591017.